Seeking Alpha

Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at...

Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at ASCO reveals booster inoculations are well-tolerated and appear to maintain long-term peptide-specific immunity and reduce disease recurrence rates. Cantor Fitzgerald starts coverage of GALE at Buy, saying its breast cancer treatment "would represent major advances in prevention of disease."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|